An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy

Author:

Zhang Ruoxin1,Jia Ming12,Xu Yuan12,Qian Danwen12,Wang Mengyun1,Zhu Meiling3,Sun Menghong14,Chang Jianhua15,Wei Qingyi126ORCID

Affiliation:

1. Cancer Institute, Collaborative Innovative Center for Cancer Medicine, Fudan University Shanghai Cancer Center, 270 Dong An Road; Xuhui District Shanghai 200032 People's Republic of China

2. Department of Oncology; Shanghai Medical College, Fudan University Shanghai Cancer Center, 270 Dong An Road; Shanghai 200032 People's Republic of China

3. Department of Oncology; Xinhua Hospital affiliated to Shanghai Jiaotong University, No. 1665 Kong Jiang Road; Shanghai 200092 People's Republic of China

4. Department of Pathology; Fudan University Shanghai Cancer Center, 270 Dong An Road; Shanghai 200032 People's Republic of China

5. Department of Medical Oncology; Fudan University Shanghai Cancer Center, 270 Dong An Road; Shanghai 200032 People's Republic of China

6. Duke Cancer Institute, Duke University Medical Center, 10 Bryn Searle Dr.; Durham NC 27710 USA

Funder

Fudan University

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3